In teasing out marketing attribution for audience actions, the last touch before conversion isn’t necessarily the one that matters most.
If you are not happy with the results below please do another search
50 search results for:
Exelixis’ cancer portfolio stumbled Thursday as the Alameda, CA-based company reported that a Phase III study of cabozantinib in combination with Roche’s Tecentriq (atezolizumab) failed to hit the primary endpoint of overall survival in second-line non-small cell lung cancer.
ImmunoGen entered into a clinical collaboration deal with Gilead Sciences Friday to evaluate the safety and efficacy of two drugs that, when used in concert, have the potential to treat AML, a blood disorder biopharma has found challenging to target.
The European Union’s health regulator has advised the use of antiviral treatments over monoclonal antibodies to treat COVID-19 in patients at risk of their condition worsening, citing concerns over decreasing effectiveness against newer virus variants.
U.S. Food and Drug Administration staff reviewers on Friday identified safety and efficacy concerns about Cytokinetics Inc.’s heart drug, according to briefing documents published on the agency’s website.
Autolus Therapeutics is calling the Phase II FELIX trial, assessing its next-generation CAR-T therapy obe-cel for leukemia, a win after an interim analysis revealed an overall remission rate of 70%.
The rush to use AstraZeneca and Daiichi-Sankyo’s drug Enhertu to treat certain types of breast cancer has far outpaced doctors’ ability to determine with certainty which patients might benefit, experts said this week at a meeting of breast cancer doctors.
Increased drug resistance in bacteria causing bloodstream infections, including against last-resort antibiotics, was seen in the first year of the coronavirus pandemic, a World Health Organization report based on data from 87 countries in 2020 showed.
The U.S. Food and Drug Administration (FDA) on Thursday approved Elanco Animal Health Inc.’s drug for cats with a type of diabetes, making it the first oral drug to be approved for the disease in animals.
One of the advantages of leveraging behavioral science in healthcare marketing is that it provides marketers with powerful tools to do what we do best: solve problems. Once we are able to identify the unique behavioral barriers at play, the science leads us toward solutions that are likely to be successful in addressing them. But what happens when we are faced with behavioral challenges that are not so clearly solvable?